Preclinical efficacy of carfilzomib in BRAF‐mutant colorectal cancer models
Proto-Oncogene Proteins B-raf
BRAF mutant colorectal cancer
immune microenvironment
BRAF mutant colorectal cancer; endoplasmic reticulum stress; immune microenvironment; immunogenic cell death; oncogene; proteasome inhibitors
proteasome inhibitors
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Antineoplastic Agents
Endoplasmic Reticulum Stress
Mice, Inbred C57BL
Mice
oncogene
Cell Line, Tumor
immunogenic cell death
Mutation
endoplasmic reticulum stress
Autophagy
Animals
Humans
Colorectal Neoplasms
Oligopeptides
RC254-282
Research Articles
DOI:
10.1002/1878-0261.13595
Publication Date:
2024-02-13T09:32:11Z
AUTHORS (19)
ABSTRACT
Serine/threonine‐protein kinase B‐raf (BRAF) mutations are found in 8–15% of colorectal cancer patients and identify a subset of tumors with poor outcome in the metastatic setting. We have previously reported that BRAF‐mutant human cells display a high rate of protein production, causing proteotoxic stress, and are selectively sensitive to the proteasome inhibitors bortezomib and carfilzomib. In this work, we tested whether carfilzomib could restrain the growth of BRAF‐mutant colorectal tumors not only by targeting cancer cells directly, but also by promoting an immune‐mediated antitumor response. In human and mouse colorectal cancer cells, carfilzomib triggered robust endoplasmic reticulum stress and autophagy, followed by the emission of immunogenic‐damage‐associated molecules. Intravenous administration of carfilzomib delayed the growth of BRAF‐mutant murine tumors and mobilized the danger‐signal proteins calreticulin and high mobility group box 1 (HMGB1). Analyses of drug‐treated samples revealed increased intratumor recruitment of activated cytotoxic T cells and natural killers, concomitant with the downregulation of forkhead box protein P3 (Foxp3)+ T‐cell surface glycoprotein CD4 (CD4)+ T cells, indicating that carfilzomib promotes reshaping of the immune microenvironment of BRAF‐mutant murine colorectal tumors. These results will inform the design of clinical trials in BRAF‐mutant colorectal cancer patients.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (60)
CITATIONS (3)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....